Study number 8547-417
Refer your friends!
Dates
Jun 11 2025-Dec 04 2025
Location
Dallas, Texas
Age
18-65
Gender
Male/Female
Smoker
Yes
Compensation
$18,895
Group
B2b
Study Details
The investigational drug in this research study is being developed for the potential treatment of obesity and potentially type 1 and 2 diabetes mellitus. Tirzepatide is an injectable prescription drug that has been approved by the FDA for chronic weight management in doses up to 15 mg once weekly, in addition to diet, exercise, and oral medications. The use of tirzepatide in combination with the study drug in this study is investigational.
Fortrea Dallas, TX is recruiting for:
-Healthy Men and Women of non-childbearing potential, age 18-65
-Body Mass Index between 27-40
-Study involves 2 separate stays totaling 9 nights at our clinic & 21 follow-up visits
-Compensation up to $18,895 may be provided for time and participation
-Refer a friend to receive $400 per qualified referral
Additional Details
B2b:
Check-in: Jun 11
Check-out: Jun 15
Outpatient visits: Jun 19, 26, Jul 3, 10, 17, 24, 31, Aug 7, 14, 21, 28, Sep 4, 11, 18
Check-in: Sep 25
Check-out: Sep 30
Outpatient visits: Oct 2, 9, 16, 23, 30 Nov 20, Dec 4